SCHEMBL8076273

SCHEMBL8076273

COC(=O)n1cc(C)c2ccccc21

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 11/20 0.67
MEN1 O00255 5/20 0.67
MAPT P10636 4/20 0.47
ALDH1A1 P00352 3/20 0.47
TFPI2 P48307 1/20 0.47
KDM4E B2RXH2 2/20 0.47
THRB P10828 1/20 0.47
LMNA P02545 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NR4A2 P43354 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2114760 0.85 L3MBTL1 (0.54) KMT2AMEN1MAPTALDH1A1TFPI2
SCHEMBL8076272 0.83 KMT2A (0.67) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL10842060 0.83 KMT2A (0.67) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL1196432 0.82 L3MBTL1 (0.62) KMT2AMEN1TFPI2L3MBTL1
SCHEMBL8076309 0.82 KMT2A (0.47) KMT2AMEN1MAPTALDH1A1TFPI2
SCHEMBL27887683 0.82 TFPI2 (0.51) KMT2AMEN1MAPTALDH1A1TFPI2
SCHEMBL10842053 0.81 KMT2A (0.65) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL27774897 0.81 KMT2A (0.65) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL30622597 0.80 TFPI2 (0.54) KMT2AMEN1MAPTALDH1A1TFPI2
SCHEMBL887130 0.80 CREBBP (0.55) KMT2AMEN1MAPTALDH1A1TFPI2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210077562-A1 ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS, AND USES ENB THERAPEUTICS, INC. 2021-03-18 US disclosed
EP-0555537-B1 Endothelin antagonists BANYU PHARMA CO LTD (JP) 2000-11-02 EP disclosed
EP-0460679-B1 Endothelin antagonistic peptide derivatives BANYU PHARMA CO LTD (JP) 1998-10-28 EP disclosed
US-5691315-A CARDIOVASCULAR DISORDERS; VASODILATOR; BRONCHODILATOR BANYU PHARMACEUTICAL CO., LTD. (JP) 1997-11-25 US disclosed
US-5614498-A OLIGOPEPTIDES, BRONCHDILATORS BANYU PHARMACEUTICAL CO., LTD. (JP) 1997-03-25 US disclosed
US-5496928-A Endothelin antagonistic substance BANYU PHARMACEUTICAL CO., LTD. (JP) 1996-03-05 US disclosed
US-5470833-A Vasodilators, bronchodilators BANYU PHARMACEUTICAL CO., LTD. (JP) 1995-11-28 US disclosed
US-5444152-A Vasolidator or bronchodilator BANYU PHARMACEUTICAL CO., LTD. (JP) 1995-08-22 US disclosed
EP-0555537-A2 Endothelin antagonistic substance BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210077562-A1 ETBR ANTAGONIST COMPOUNDS, COMPOSITIONS, AND USES EDNRB, EDNRA, LTB4R KMT2A 2952/4885MEN1 4675/4885MAPT 4661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.